evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

150 questions · 161 findings · 19 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 10 · 6.2%GRADE not reported 14 · 8.7%Very low 32 · 19.9%Low 65 · 40.4%Moderate 34 · 21.1%High 6 · 3.7%

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Show 7 more findings

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

2 findings from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Participant satisfaction · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx

The review found no eligible studies for this question.

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review

Intervention not reported

Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I

It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).

1 finding from 1 review

Two doses of HPV vaccine vs three doses of HPV vaccine

Antibody response (immunogenicity) · 9‐ to 15‐year‐old females

Two doses of HPV vaccine probably leads to lower antibody response (immunogenicity) compared with three doses of HPV vaccine (moderate certainty).

1 finding from 1 review

Mycophenolate mofetil vs azathioprine (AZA)

Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients

Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).

1 finding from 1 review

Red blood cell transfusion vs no transfusion

Erythrocyte alloantibody formation Laboratory assessment · women with postpartum iron deficiency anaemia

It is very uncertain whether red blood cell transfusion changes erythrocyte alloantibody formation Laboratory assessment compared with non‐transfusion (Comparison 2) (very low certainty).

1 finding from 1 review

Immunologic response to YF vaccine in HIV‐infected adults before HIV diagnosis, vs immunologic response to YF vaccine

Immunogenicity: Adequate antibody response (NT ≥1:10), · adults with HIV infection

Immunologic response to YF vaccine in HIV‐infected adults before HIV… may leads to lower immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (low certainty).

1 finding from 1 review

Immunologic response to YF vaccine in HIV‐infected children vs immunologic response to YF vaccine

Immunogenicity: Adequate antibody response (NT ≥1:10), · Children with HIV infection

It is very uncertain whether immunologic response to YF vaccine in HIV‐infected children changes adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).

1 finding from 1 review